ClinicalTrials.gg
RecruitingNCT07661927NoELAUpdated Oct 5, 2026

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

A Phase 2 interventional study of Removing Endocrine Therapy in Breast Cancer (Early Breast Cancer), sponsored by UNICANCER. Recruiting at 41 sites in France. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by UNICANCER · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
700
Allocation
Not applicable
Ages
60 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.

Planned enrollment
16th of 59
700 · median 170
Started
2026
with 5 others
Phase 2
28 of 64
8 open now
Primary completion
2033-07
later than 24 of 26 live
Registered
63rd of 64
by date

Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 16th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 28 in phase 2, reaches primary completion later than 24 of the 26 other live ones, and was the 63rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 60 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by UNICANCER, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse. It will also evaluate the prognosis of these participants compared to participants who received standard treatment with hormone therapy in another study, estimate the risk of specific recurrence, cardiovascular and bone health, and participants' quality of life.

All participants will have undergone surgery and possibly radiation therapy, but unlike standard care, they will not receive hormone therapy afterward. Participants will be enrolled for two years and followed for up to five years after the last participant is enrolled in the trial to monitor for long-term cancer recurrence.

Read the detailed description

Breast cancer is the most frequently diagnosed cancer among women worldwide. Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors represent the predominant subtype and are generally associated with favorable outcomes. Adjuvant endocrine therapy (ET), including tamoxifen and aromatase inhibitors, constitutes a cornerstone of treatment for HR+/HER2- early breast cancer and has demonstrated reductions in recurrence and mortality in large randomized trials and meta-analyses. However, these benefits were mainly established in populations including patients with a broader spectrum of recurrence risk.

The implementation of mammography screening programs has increased the detection of small, early-stage breast cancers, including tumors with excellent prognosis and very low risk of recurrence. In postmenopausal women with small node-negative Luminal A tumors, recurrence rates are particularly low, raising concerns regarding potential overtreatment and the balance between treatment benefit and toxicity.

Although ET is effective, its long-term administration is associated with substantial treatment burden and persistent toxicities, including musculoskeletal symptoms, vasomotor symptoms, fatigue, sexual dysfunction, mood disturbances, and bone loss. These adverse effects may significantly affect quality of life and contribute to treatment discontinuation. Observational data have suggested that ET-related quality-of-life impairment may persist longer than chemotherapy-related effects, particularly in postmenopausal women.

Retrospective studies have suggested that the absolute benefit of ET may be limited in selected patients with very low-risk disease, especially among older women with small, low-grade HR+/HER2- tumors. Furthermore, simulation models estimating individualized treatment benefit indicate that the absolute overall survival gain associated with ET in some low-risk subgroups may be minimal, with high numbers needed to treat.

Advances in biological characterization have enabled identification of Luminal A tumors, characterized by strong hormone receptor expression, low proliferative activity, and favorable prognosis. Combining biological characteristics with clinicopathological features such as age, tumor size, grade, and nodal status allows the identification of a subgroup of postmenopausal patients with exceptionally low risk of relapse.

NoELA was developed to prospectively evaluate a therapeutic de-escalation strategy consisting of omission of adjuvant ET in postmenopausal women presenting with very low-risk HR+/HER2- early breast cancer with Luminal A phenotype. The study focuses on patients expected to derive limited benefit from ET while remaining exposed to its long-term toxicity burden.

The study also aims to generate evidence supporting more individualized treatment strategies and improved shared decision-making by better quantifying the risk-benefit balance of ET omission in this population. In addition, comparison with external real-world data derived from patients treated with standard ET will help contextualize outcomes and improve the external validity of the findings.

03

Conditions studied

  • Breast Cancer (Early Breast Cancer)

Browse trials for

Keywords

  • breast cancer
  • hormone therapy
  • de-escalation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (underwent bilateral oophorectomy or non-chemo induced amenorrhea for 12 or more months) female participant ≥60 years of age.
  • New diagnosis of invasive carcinoma of the breast (ductal, tubular or mucinous) with primary tumor ≤1 cm on microscopic exam with no evidence of nodal or distant disease.
  • Contralateral breast described as BI-RADS (Breast Imaging-Reporting And Data System) 1 or 2 in diagnostic imaging.
  • Negative axillary node involvement by sentinel node or axillary node dissection (pN0) or Clinically negative axillary node involvement (cN0) after mandatory ultrasound exploration without surgical exploration of the axilla if Breast Conservative Surgery (BCS) was performed.
  • Estrogen Receptor (ER) positive (≥ 50%) and Progesterone Receptor(PR) positive (> 20%), Ki67 low (≤15%) and negative (IHC or In Situ Hybridization approach) according to ASCO (American Society of Clinical Oncology) criteria.
  • Histological grade scored on the invasive component, 1 or 2 if pT1a or grade 1 if pT1b.
  • Treated by mastectomy or BCS with microscopically clear resection margins defined as "no-ink on tumor" or ≥1 mm for invasive and non-invasive disease or no residual disease on re-excision.
  • If BCS was performed, participants must have received or have scheduled local radiotherapy (RT) within 3 months after surgery
  • No indication of adjuvant chemotherapy.
  • The participant is willing and able to comply with the protocol for the duration of the study, including scheduled visits, treatment strategy, laboratory tests and other study procedures.
  • Participants must be affiliated with a Social Security System (or equivalent).
  • The participant must have signed a written form before any trial-specific procedures. When the participant is physically unable to give written consent, an impartial witness of her choice, independent from the investigator or the sponsor, can confirm the participant's consent in writing.

Exclusion criteria

Exclusion Criteria:

  • Have received any treatment, including hormone therapy and chemotherapy.
  • Have received or are eligible for adjuvant chemotherapy.
  • Absolute for RT in case of BCS or patients who were treated with partial breast irradiation.
  • Have been treated with mastectomy and with adjuvant radiotherapy received or scheduled.
  • Invasive lobular breast cancer.
  • Bilateral breast cancer or history of other invasive ipsi- or contralateral breast cancer.
  • Multifocal or multicentric disease.
  • Disease limited to microinvasion only (\< 1 mm).
  • Evidence of lymphovascular invasion.
  • History of non-breast cancer if not disease-free for > 5 years and considered low risk of recurrence except for treated carcinoma in situ of the cervix, endometrium or colon, melanoma in situ and basal or squamous cell carcinoma of the skin.
  • Non-malignant severe disease associated with a \< 10 years.
  • Women with BRCA1, BRCA2 or other high-risk breast cancer predisposing deleterious germline mutations.
  • Enrolled in another therapeutic study within 30 days prior to inclusion.
  • Unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.
  • Persons deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    No Endocrine Therapy

    The endocrine therapy will not be received by the participant during the study.

    Drug: Removing Endocrine Therapy

Interventions

  • DrugRemoving Endocrine Therapy

    The standard of care endocrine therapy (Tamoxifene, Letrozole, Anastrozole or Exemestane) will not be received by the participant during the study.

06

What researchers measure

Primary outcomes

  1. Relapse-free interval

    Relapse-free interval (RFI) is defined as the delay between initial treatment and the first occurrence of i) ipsilateral breast tumor recurrence, ii) distant or locoregional recurrence or iii) death from breast cancer, according to the STEEP system definition version 2.0 (Tolaney SM et al., J Clin Oncol 2021)

    Time frame: At 5 years after the last treatment

Secondary outcomes

  1. Incidence of Ipsilateral Ductal Carcinoma In Situ (DCIS)

    Time frame: At 5 years after the last treatment

  2. Incidence of invasive contralateral breast cancer

    Time frame: At 5 years after the last treatment

  3. Distant disease free survival (DDFS)

    Distant disease free survival is defined as the delay between date of inclusion and distant tumor relapse or death from any cause, whichever occurs first.

    Time frame: At 5 years after the last treatment

  4. Relapse free survival (RFS)

    Relapse-free survival is defined as the delay between date of inclusion and tumor relapse (local, regional, or distant) or death from any cause, whichever occurs first.

    Time frame: 5 years after the last treatment

  5. Overall survival (OS)

    The overall survival is the length of time from randomization that patients enrolled in the study are still alive.

    Time frame: At 5 years after the last treatment

  6. Quality of life questionnaire - Core 30 (QLQ-C30)

    Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At baseline, 6 months, 1 year, and then annually until 5 years after the last inclusion

  7. Quality of Life Questionnaire - Breast cancer module (QLQ-BR42)

    This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR42 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items.

    Time frame: At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion

  8. Hospital anxiety and depression scale (HADS)

    The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale. Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T). Each item is rated on a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), for a total score ranging from 0-21 for each subscale. The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.

    Time frame: At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion

  9. Bone-related events and osteopenia/osteoporosis diagnosis, dyslipidemia (hypercholesterolemia and hypertriglyceridemia) and cardiovascular events (myocardial infarction, stroke, and thromboembolic events), as per CTCAE v6.0

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 6 (NCI-CTCAE v6) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout study completion, up to 5 years after the last inclusion

07

Study locations

10 of 41 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2033, 84 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 84 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 22, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jul 6, 2033
CompletionEst.
Jul 6, 2033
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites changed recruiting status (9 now active, not recruiting, 9 now recruiting)
Show 18 sites
  • Sainte Catherine, Institut du Cancer Avignon-Provence · Avignon, FranceNot yet recruiting→Active, not recruiting
  • CHCB · Bayonne, FranceNot yet recruiting→Active, not recruiting
  • CH Boulogne sur mer · Boulogne-sur-Mer, FranceNot yet recruiting→Active, not recruiting
  • Clinique Pasteur Lanroze · Brest, FranceNot yet recruiting→Active, not recruiting
  • Pole Sante Leonard de Vinci- Roc37 · Chambray-lès-Tours, FranceNot yet recruiting→Recruiting
  • Centre Leonard de Vinci · Dechy, FranceNot yet recruiting→Active, not recruiting
  • CHD Vendée · La Roche-sur-Yon, FranceNot yet recruiting→Recruiting
  • Centre Guillaume le Conquérant · Le Havre, FranceActive, not recruiting→Recruiting
  • Centre Oscar Lambret · Lille, FranceActive, not recruiting→Recruiting
  • Centre Léon Bérard · Lyon, FranceActive, not recruiting→Recruiting
  • Hôpital privé Jean Mermoz · Lyon, FranceNot yet recruiting→Active, not recruiting
  • CHU Orleans · Orléans, FranceNot yet recruiting→Active, not recruiting
  • Institut Curie · Paris, FranceActive, not recruiting→Recruiting
  • Centre Eugène Marquis · Rennes, FranceNot yet recruiting→Recruiting
  • Institut Curie · Saint-Cloud, FranceNot yet recruiting→Recruiting
  • CHU de Saint Etienne · Saint-Priest-en-Jarez, FranceNot yet recruiting→Active, not recruiting
  • Centre de lutte contre le cancer - Paul Strauss · Strasbourg, FranceNot yet recruiting→Active, not recruiting
  • IUCT-Oncopole · Toulouse, FranceNot yet recruiting→Recruiting
Oct 5, 2026
Site contacts
Changed at 13 sites. See the sites
Show 13 sites
  • Sainte Catherine, Institut du Cancer Avignon-Provence · Avignon, FranceContact removed (no phone or email listed)
  • CHCB · Bayonne, FranceContact removed (no phone or email listed)
  • CH Boulogne sur mer · Boulogne-sur-Mer, FranceContact removed (no phone or email listed)
  • Clinique Pasteur Lanroze · Brest, FranceContact removed (no phone or email listed)
  • Centre Leonard de Vinci · Dechy, FranceContact removed (no phone or email listed)
  • Centre Guillaume le Conquérant · Le Havre, FranceContact added (no phone or email listed)
  • Centre Oscar Lambret · Lille, FranceContact added (no phone or email listed)
  • Centre Léon Bérard · Lyon, FranceContact added (no phone or email listed)
  • Hôpital privé Jean Mermoz · Lyon, FranceContact removed (no phone or email listed)
  • CHU Orleans · Orléans, FranceContact removed (no phone or email listed)
  • Institut Curie · Paris, FranceContact added (no phone or email listed)
  • CHU de Saint Etienne · Saint-Priest-en-Jarez, FranceContact removed (no phone or email listed)
  • Centre de lutte contre le cancer - Paul Strauss · Strasbourg, FranceContact removed (no phone or email listed)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    18 sites changed recruiting status (9 now active, not recruiting, 9 now recruiting)
    Show 18 sites
    • Sainte Catherine, Institut du Cancer Avignon-Provence · Avignon, FranceNot yet recruiting→Active, not recruiting
    • CHCB · Bayonne, FranceNot yet recruiting→Active, not recruiting
    • CH Boulogne sur mer · Boulogne-sur-Mer, FranceNot yet recruiting→Active, not recruiting
    • Clinique Pasteur Lanroze · Brest, FranceNot yet recruiting→Active, not recruiting
    • Pole Sante Leonard de Vinci- Roc37 · Chambray-lès-Tours, FranceNot yet recruiting→Recruiting
    • Centre Leonard de Vinci · Dechy, FranceNot yet recruiting→Active, not recruiting
    • CHD Vendée · La Roche-sur-Yon, FranceNot yet recruiting→Recruiting
    • Centre Guillaume le Conquérant · Le Havre, FranceActive, not recruiting→Recruiting
    • Centre Oscar Lambret · Lille, FranceActive, not recruiting→Recruiting
    • Centre Léon Bérard · Lyon, FranceActive, not recruiting→Recruiting
    • Hôpital privé Jean Mermoz · Lyon, FranceNot yet recruiting→Active, not recruiting
    • CHU Orleans · Orléans, FranceNot yet recruiting→Active, not recruiting
    • Institut Curie · Paris, FranceActive, not recruiting→Recruiting
    • Centre Eugène Marquis · Rennes, FranceNot yet recruiting→Recruiting
    • Institut Curie · Saint-Cloud, FranceNot yet recruiting→Recruiting
    • CHU de Saint Etienne · Saint-Priest-en-Jarez, FranceNot yet recruiting→Active, not recruiting
    • Centre de lutte contre le cancer - Paul Strauss · Strasbourg, FranceNot yet recruiting→Active, not recruiting
    • IUCT-Oncopole · Toulouse, FranceNot yet recruiting→Recruiting
    Site contacts Changed at 13 sites. See the sites
    Show 13 sites
    • Sainte Catherine, Institut du Cancer Avignon-Provence · Avignon, FranceContact removed (no phone or email listed)
    • CHCB · Bayonne, FranceContact removed (no phone or email listed)
    • CH Boulogne sur mer · Boulogne-sur-Mer, FranceContact removed (no phone or email listed)
    • Clinique Pasteur Lanroze · Brest, FranceContact removed (no phone or email listed)
    • Centre Leonard de Vinci · Dechy, FranceContact removed (no phone or email listed)
    • Centre Guillaume le Conquérant · Le Havre, FranceContact added (no phone or email listed)
    • Centre Oscar Lambret · Lille, FranceContact added (no phone or email listed)
    • Centre Léon Bérard · Lyon, FranceContact added (no phone or email listed)
    • Hôpital privé Jean Mermoz · Lyon, FranceContact removed (no phone or email listed)
    • CHU Orleans · Orléans, FranceContact removed (no phone or email listed)
    • Institut Curie · Paris, FranceContact added (no phone or email listed)
    • CHU de Saint Etienne · Saint-Priest-en-Jarez, FranceContact removed (no phone or email listed)
    • Centre de lutte contre le cancer - Paul Strauss · Strasbourg, FranceContact removed (no phone or email listed)
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07661927
Lead sponsor
UNICANCER
Collaborators
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 6, 2026
Primary completion
Jul 6, 2033 (estimated)
Completion
Jul 6, 2033 (estimated)
Last update
Oct 5, 2026

Study contacts

Unicancer Project Leader
Contact
a-poitou@unicancer.fr
0033 6 58 43 58 94
Jean-Yves PIERGA, MD
principal investigator · Institut Curie
José Luis SANDOVAL, MD
principal investigator · University Hospital, Geneva

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion